Luis Villa, MD
Hematology & Oncology · Miami, FLNPI 1932197233
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,120 of the $1,324 with a category attached, or 84.6%. It is spread thinly across 18 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $649, 2.3 times the $286 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in FL, where the typical reported total is $3,884.
Across 59 payments — averaging $22.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$297
- AstraZeneca$180
- Array Biopharma Inc$153
- Merck$131
- Novartis$129
- Seagen Inc.$100
- plus $334 from 12 others
Across 3 payments — averaging $24,592 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- EMD Serono, Inc.$74K
What the payments were for
- Food & beverage$1,12085%
- Education$20415%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 15 | $297 |
| AstraZeneca | 8 | $180 |
| Array Biopharma Inc | 6 | $153 |
| Merck | 5 | $131 |
| Novartis | 6 | $129 |
| Seagen Inc. | 1 | $100 |
| Bristol Myers Squibb | 3 | $56 |
| Lilly USA, LLC | 3 | $49 |
| Pfizer | 2 | $34 |
| Puma Biotechnology, Inc. | 2 | $33 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Pharmacosmos Therapeutics Inc. | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Caris MPI, Inc. | 1 | $22 |
| Incyte Corporation | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Tempus AI, Inc | 1 | $17 |
| Genentech USA, Inc. | 1 | $15 |
How this compares
$1,324 in reported general payments places this provider in the 30th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TabrectaCapmatinib Hydrochloride | 12 | $270,229 |
| Abiraterone Acetate | 11 | $27,870 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,279 |
| EliquisApixaban | 11 | $6,530 |
| Exemestane | 27 | $6,256 |
| Anastrozole | 88 | $676 |
| Letrozole | 39 | $640 |
| Tamoxifen Citrate | 18 | $310 |
| Duloxetine Hcl | 15 | $296 |
| Methylprednisolone | 15 | $94 |
| Acyclovir | 16 | $39 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisTabrecta | $129 | $270,22912 claims |
| PfizerEliquis | $34 | $6,53011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Miami
- Steven FeinMiami$1M
- Srikanth NagallaMiami$639K
- Neil NagovskiMiami$530K
- Carl LandgrenMiami$517K
- Raja MudadMiami$422K
- George NahasMiami$364K
- Fernando de ZarragaMiami$333K
- Mikkael SekeresMiami$278K
- Krishna KomanduriMiami$187K
- Estelamari RodriguezMiami$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.